American CryoStem Corporation

33 articles about American CryoStem Corporation

• American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

  3/4/2022

  American CryoStem Corporation a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome.

• American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial

  12/22/2021

  American CryoStem Corporation a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced that its clinical study team has completed recruiting subjects for its Investigational New Drug Phase I Clinical Trial for Post-concussion syndrome.

• American CryoStem Completes Clinical Protocol Design for Long COVID Study

  11/30/2021

  American CryoStem Corporation, a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies announced completion of its Phase I clinical protocol design for the treatment of Long COVID.

• American CryoStem Announces the Addition of John Schwartz, PhD to Its Advisory Board

  11/23/2021

  American CryoStem Corporation, a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced that it has added John "Jay" Schwartz, PhD to its Scientific and Medical Advisory Board.

• American CryoStem to Study New Standardized Treatment Protocols for Wound Healing

  11/16/2021

  American CryoStem Corporation, a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates.

• American CryoStem Enters into an Agreement to Exchange Shares held by ACS Global, Inc

  11/12/2021

  American CryoStem Corporation, a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for 1,000,000 shares of preferred stock.

• American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

  5/6/2021

  American CryoStem Corporation announced that it has signed a Letter of Intent with Advanced Regenerative Associates, LLC of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb ischemia associated with type II diabetes, burns, and other systemic conditions.

• American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

  3/11/2021

  American CryoStem Corporation a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells, for use in its FDA approved IND Phase I Clinical Trial.

• American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement

  2/25/2021

  American CryoStem Corporation, a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced that it has entered into an Agreement with BioTherapeutic Labs Corp. an FDA registered Umbilical Cord Tissue Manufacturing Company headquartered in Boca Raton, Florida.

• American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols

  1/6/2021

  American CryoStem Corporation, a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has entered into a Cooperative Research and Development Agreement authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade.

• American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

  12/1/2020

  American CryoStem Corporation a clinical-stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has commenced recruiting subjects for its IND Phase I Clinical Trial and added an additional sub-investigator to the ATCELL™ Clinical Trial team.

• American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial

  9/23/2020

  American CryoStem Corporation is a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular therapy processing.

• American CryoStem Issues Shareholder Update Letter

  8/4/2020

  American CryoStem Corporation is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone.

• American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market

  6/29/2020

  American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries today announced that $168,000 of the Company's convertible debt that was recorded in the March 31, 2020 10-Q balance sheet of CRYO has been successfully converted into equity.

• COO Tony Dudzinski Highlights American CryoStem Corporation’s Path To Current And Future Success

  9/12/2017

• American CryoStem Corporation Release: COO Anthony Dudzinski Was Interviewed On Uptick Network On Product Importance And Company Improvements

  8/14/2017

• American CryoStem Corporation Appoints Nobel Prize Nominee And One Of The Leading Stem Cell Experts Vincent C. Giampapa, M.D. To Its Medical And Scientific Advisory Board

  4/15/2016

• American CryoStem Corporation Expands With New Stem Cell Processing And Cryogenic Storage Laboratory

  4/7/2016

• American CryoStem Corporation Retains Investor Relations Partners As Investor Relations Counsel

  4/1/2016

• American CryoStem Corporation Announces Agreement With The Nanoranch Division Of UHV Technologies For Cancer Research Utilizing ATCELL™

  6/18/2014